{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"producer": "iLovePDF", "creator": "PDFMiner", "creationdate": "", "moddate": "2025-09-14T06:45:35+00:00", "total_pages": 280, "source": "/home/thiru/draft-oasis-e1-manual-04-28-2024_edited.pdf"}, "page_content": "Medication Follow-up \n\nMedication Intervention \n\nPatient/Caregiver High-Risk Drug \nEducation \n\nM2020 \n\nManagement of Oral Medications \n\nM2030 \n\nO0110 \n\nO0350 \n\nM1041 \n\nM1046 \n\nManagement of Injectable \nMedications \nSpecial  Treatments,  Procedures, \nand Programs \nPatient\u2019s COVID-19 vaccination is up \nto date \nInfluenza Vaccine Data Collection \nPeriod \nInfluenza Vaccine Received \n\nM2401 \n\nIntervention Synopsis \n\nSOC \nX \n\nROC \nX \n\nFU \n\nTRN \n\nDC  DAH \nX \n\nItem Uses \nPRA \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nQ \n\nQ \n\nQ \n\nQ \n\nQ, PRA, \n$VBP \nPRA \n\nPRA \n\nQ \n\nQ \n\nQ \n\nQ \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nX \n\nAppendix B \n\nSection \nSECTION N  \nMEDICATIONS \n\nSECTION O  \nSPECIAL  \nTREATMENT, \n\nPROCEDURES, and \nPROGRAMS \n\nSECTION Q  \nPARTICIPATION  \nin ASSESSMENT \nand GOAL \nSETTING \n\nOASIS-E1 \nEffective 01/01/2025 \nCenters for Medicare & Medicaid Services \n\n257\n\fAppendix C \n\nOASIS-E1 Instruments \n\nAPPENDIX C: OASIS-E1 INSTRUMENTS \nThe final OASIS-E1 All Items and time point versions of the instrument are available in the Downloads section of \nthe CMS OASIS Data Sets webpage at https://www.cms.gov/medicare/quality/home-health/oasis-data-sets  \n\nOASIS-E1 \nEffective 01/01/2025 \nCenters for Medicare & Medicaid Services \n\n258\n\fAppendix D \n\n                                                       Description of Changes from OASIS-E to OASIS-E1 \n\nAPPENDIX D: DESCRIPTION OF CHANGES FROM OASIS-E TO OASIS-E1", "type": "Document"}}